Poniard Pharmaceuticals, Inc.
PARD · OTC
9/30/2011 | 6/30/2011 | 3/31/2011 | 12/31/2010 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $287 | $442 | $333 | $105 |
| G&A Expenses | $3,461 | $3,396 | $2,899 | $3,393 |
| SG&A Expenses | $3,461 | $3,396 | $2,899 | $3,393 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1,217 |
| Operating Expenses | $3,748 | $3,838 | $3,232 | $4,715 |
| Operating Income | -$3,748 | -$3,838 | -$3,232 | -$4,715 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,748 | $3,838 | $3,232 | $4,715 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,771 | -$3,858 | -$3,246 | -$5,167 |
| % Margin | – | – | – | – |
| EPS | -2.4 | -2.8 | -2.4 | -4.09 |
| % Growth | 14.3% | -16.7% | 41.3% | – |
| EPS Diluted | -2.4 | -2.8 | -2.4 | -4.09 |
| Weighted Avg Shares Out | 1,498 | 1,489 | 1,352 | 1,262 |
| Weighted Avg Shares Out Dil | 1,498 | 1,489 | 1,352 | 1,262 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $10 | $14 |
| Interest Expense | $23 | $23 | $24 | $466 |
| Depreciation & Amortization | $311 | $317 | $323 | $324 |
| EBITDA | -$3,437 | -$3,521 | -$2,909 | -$4,391 |
| % Margin | – | – | – | – |